Move to lower cancer treatment price
BEIJING: Imported drugs are no longer subject to tariffs and VAT (value added tax) has been slashed in efforts to make medication more affordable, as American biochemist Wang Xiaodong reports.
The cost of imported cancer drugs is expected to fall dramatically as a result of recent government measures, according to the National Health Commission.
On May 1, import tariffs were lifted on 103 of the 138 antineoplastic drugs – which can prevent or slow the growth of tumours – available on the Chinese market, and the VAT levied on them was also reduced.
Authorities will also adopt measures to lower costs, such as price negotiations with manufacturers, greater use of centralised government procurement and the inclusion of a wider range of antineoplastic drugs in the national healthcare insurance programme, Zeng Yixin, vice-minister in charge of the commission, told a media briefing.
The moves are aimed at reducing the heavy financial burden that inadequate medical insurance cover can impose on some cancer patients, especially as the disease is a major cause of poverty in rural areas.
A report by the Cancer Hospital at the Chinese Academy of Medical Sciences showed that more than 3.8 million new cases are reported in China every year.
“Cancer has become the leading threat to people’s lives and health because of a number of causes – including the ageing population, industrialisation and unhealthy lifestyles – and the incidence of the disease is rising,” Zeng said.
“Although new, effective antineoplastic drugs are available, some patented drugs are extremely expensive, and that places a heavy financial burden on patients.” — China Daily/Asia News Network